| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
New Corporate Brand to be Unveiled at AASLD Liver Meeting® 2023 with Interim Data
Alliance Global Partners analyst James Molloy initiates coverage on Vaccitech (NASDAQ:VACC) with a Buy rating and announces ...